SuperworthTG Therapeutics PE ratio TGTX
Share price divided by earnings per share over the last twelve months, since 2025.
- Today, Oct 23, 2026
- 19.8×
- Peer median
- 97.0×
TG Therapeutics' PE ratio is 19.8× as of Oct 23, 2026: a share price of $54.17 against $2.74 of earnings per share over the last twelve months.
The median for 10 large drugmakers of a similar size is 97.0×.
PE ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 19.8× | 10.1× | 21.0× |
| 2025 | 11.1× | 11.1× | 167× |
Against its peers
Companies in Drug Manufacturers - General nearest TG Therapeutics' size, closest first, today.
| Company | PE ratio |
|---|---|
| TGTXTG Therapeutics | 19.8× |
| PTGXProtagonist Therapeutics | 134× |
| CORTCorcept Therapeutics | 204× |
| ALKSAlkermes plc. | 115× |
| AMRXAmneal Pharmaceuticals | 41.6× |
| BMRNBiomarin Pharmaceutical | 151× |
| LGNDLigand Pharmaceuticals | 32.3× |
| KNSAKiniksa Pharmaceuticals International | 79.1× |
| JAZZJazz Pharmaceuticals | 14.6× |
| INDVIndivior Pharmaceuticals | 12.4× |
| ARQTArcutis Biotherapeutics | 142× |
| Peer median | 97.0× |
Where TG Therapeutics ranks
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on TG Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.